SCHEMBL5403852

SCHEMBL5403852

COC(=O)C(Cc1cccc(Cl)c1)NC(=O)OC(C)(C)C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 2/20 0.69
KLK5 Q9Y337 1/20 0.58
CTSS P25774 7/20 0.53
CTSK P43235 6/20 0.53
CTSB P07858 4/20 0.53
ACE P12821 1/20 0.51
CYP3A4 P08684 1/20 0.50
SCN9A Q15858 1/20 0.50
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
MAPK1 P28482 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
EPHX2 P34913 1/20 0.47
PYGL P06737 1/20 0.47
NOS2 P35228 1/20 0.46
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
KMT2A Q03164 1/20 0.45
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29855016 1.00 CTSL (0.69) CTSLKLK5CTSSCTSKCTSB
SCHEMBL4917443 1.00 CTSL (0.69) CTSLKLK5CTSSCTSKCTSB
SCHEMBL16460171 0.90 CTSL (0.66) CTSLKLK5CTSSCTSKCTSB
SCHEMBL16460169 0.90 CTSL (0.66) CTSLKLK5CTSSCTSKCTSB
SCHEMBL1519629 0.89 CTSL (0.74) CTSLKLK5CTSSCTSKCTSB
SCHEMBL1519627 0.89 CTSL (0.74) CTSLKLK5CTSSCTSKCTSB
SCHEMBL30461919 0.89 CTSL (0.74) CTSLKLK5CTSSCTSKCTSB
SCHEMBL3553561 0.89 CTSL (0.74) CTSLKLK5CTSSCTSKCTSB
SCHEMBL32677245 0.89 CTSL (0.54) CTSLCTSSCTSKCTSBPYGL
SCHEMBL16095104 0.87 KLK5 (0.54) CTSLKLK5CTSSCTSKCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117279655-A Pharmaceutical use of cyclic peptide compounds 中外制药株式会社 2023-12-22 CN disclosed
US-7202269-B2 GlyT2 modulators JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-10 US disclosed
US-20050119245-A1 GlyT2 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-02 US disclosed
WO-2005044810-A1 GLYT2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119245-A1 GlyT2 modulators GLRB, GLRA1, GLRA2 CTSL 4205/4885KLK5 4382/4885CTSS 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.